6 Undervalued Chemicals Stocks for Friday, November 22
Discover the top 6 undervalued Chemicals stocks for Friday, November 22 based on AAII’s Stock Grades.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bon Natural Life Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People’s Republic of China, Europe, North America, and the Middle East. The company offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. It sells its products through direct distributors. The company serves manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company has a strategic partnership with Tigerbone Group Limited. Bon Natural Life Limited was founded in 2006 and is headquartered in Xi'an, the People’s Republic of China.
Commentary & Analysis
6 Undervalued Pharmaceuticals Stocks for Monday, August 26
Discover the top 6 undervalued Pharmaceuticals stocks for Monday, August 26 based on AAII’s Stock Grades.Omar Beirat
6 Undervalued Pharmaceuticals Stocks for Tuesday, July 09
Discover the top 6 undervalued Pharmaceuticals stocks for Tuesday, July 09 based on AAII’s Stock Grades.Eunice Kim
3 Undervalued Pharmaceuticals Stocks for Friday, May 31
Discover the top 3 undervalued Pharmaceuticals stocks for Friday, May 31 based on AAII’s Stock Grades.Jenna Brashear
7 Undervalued Pharmaceuticals Stocks for Friday, February 09
Discover the top 7 undervalued Pharmaceuticals stocks for Friday, February 09 based on AAII’s Stock Grades.Jenna Brashear
Financial Summary
| Share Statistics | BON | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7.1 | $3,892.9 | 5% |
|
| Shares Out (Mil) | 5.2 | 104.4 | 14% |
|
| Institutional Ownership | 32.6% | 79.6% | 14% |
|
| Float (Mil) | 6.0 | 118.7 | 14% |
|
| Beta | -0.24 | 0.81 | 3% |
|
| Avg Daily Volume (000s) | 10 | 146 | 17% |
|
| Price Change (52-week) |
(41.8%) | 78.7% | 22% |
|
| Growth | BON | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 0.5% | 4.0% | 19% |
|
| Net Income (5yr) | (21.7%) | 0.2% | 19% |
|
| EPS (5yr) | (14.9%) | 1.9% | 19 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.8% | (15.3%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BON | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $19 | $4,180 | 12% |
|
| Net Income (TTM) (Mil) | ($2) | $70 | 37% |
|
| EPS (TTM) | ($0.724) | $0.300 | 24% |
|
| Operating Cash Flow (TTM) (Mil) | $0 | $397 | 32% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $1,584 | 17% |
|
| Enterprise Value (Q1) (Mil) | $16 | $5,401 | 10% |
|
| Valuation | BON | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.12 | 1.51 | 2% |
|
| P/E | na | 21.6 | na |
|
| Dividend Yield | 0.0% | 1.2% | 0% |
|
| PEG (5yr hist) | na | 1.8 | na |
|
| Ratios | BON | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 22.1% | 27.8% | 24% |
|
| Net Margin | (60.4%) | 3.8% | 10% |
|
| ROA | (2.9%) | 2.2% | 33% |
|
| ROE | (4.2%) | 4.6% | 32% |
|
| Liabilities to Assets | 31.9% | 53.1% | 23% |
|
| F-Score | 3 | 5 | na |
|
Bon Natural Life Limited did not pass any screens on 10/2/2026.
